Olaratumab for the treatment of soft-tissue sarcoma.
MetadataShow full item record
The outcome for patients with unresectable/metastatic soft tissue sarcoma remains poor with few treatment options. In the first line setting, a number of randomized trials have shown no difference in overall survival between combination anthracycline schedules and single agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-α, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to approval of olaratumab in combination with doxorubicin in adult anthracycline-naive unresectable soft tissue sarcoma. In this review, we describe some of the preclinical and early clinical data of olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.
Version of record
Antineoplastic Agents, Immunological
Clinical Trials as Topic
Drug Evaluation, Preclinical
Molecular Targeted Therapy
Sarcoma Clinical Trials (R Jones)
License start date
Future Oncol, 2017, 13 (24), pp. 2151 - 2157